EDAP TMS S.A. shares have pushed lower in H2 FY'23, presenting an opportunity to add on weakness. EDAP's Q1 revenues were up 13.8% YoY, with HIFU sales up around 40% YoY. On examination, sentiment and ...

EDAP continues to rate higher in 2023. Positive phase 2 data investigating HIFU in rectal endometriosis adds another inflection point for investors to work by. We revised our price targets to ~$18.

EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates ...